Literature DB >> 29314611

Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.

Danilo Ritz1, Emiliano Sani2, Hanna Debiec3,4, Pierre Ronco3,4, Dario Neri5, Tim Fugmann1.   

Abstract

The interaction between HLA class II peptide complexes on antigen-presenting cells and CD4+ T cells is of fundamental importance for anticancer and antipathogen immunity as well as for the maintenance of immunological tolerance. To study CD4+ T cell reactivities, detailed knowledge of the presented peptides is necessary. In recent years, dramatic advances in the characterization of membranal and soluble HLA class I peptidomes could be observed. However, the same is not true for HLA class II peptidomes, where only few studies identify more than hundred peptides. Here we describe a MS-based workflow for the characterization of membranal and soluble HLA class II DR and DQ peptidomes. Using this workflow, we identify a total of 8595 and 3727 HLA class II peptides from Maver-1 and DOHH2 cells, respectively. Based on this data, a motif-based binding predictor is developed and compared to NetMHCIIpan 3.1. We then apply the workflow to human plasma, resulting in the identification of between 34 and 152 HLA-DR and between 100 and 180 HLA-DQ peptides, respectively. Finally, we implement a data-independent acquisition workflow to increase reproducibility and sensitivity of HLA class II peptidome characterizations.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  DIA; HLA class II; HLA peptidomics; biomarker; immunopeptidomics

Mesh:

Substances:

Year:  2018        PMID: 29314611      PMCID: PMC6003597          DOI: 10.1002/pmic.201700246

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  47 in total

1.  Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.

Authors:  M Peretti; J Villard; E Barras; M Zufferey; W Reith
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

2.  Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.

Authors:  Nancy H Gudgeon; Graham S Taylor; Heather M Long; Tracey A Haigh; Alan B Rickinson
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Development and validation of a spectral library searching method for peptide identification from MS/MS.

Authors:  Henry Lam; Eric W Deutsch; James S Eddes; Jimmy K Eng; Nichole King; Stephen E Stein; Ruedi Aebersold
Journal:  Proteomics       Date:  2007-03       Impact factor: 3.984

4.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

5.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

Review 6.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

7.  Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples.

Authors:  Tina Heyder; Maxie Kohler; Nataliya K Tarasova; Sabrina Haag; Dorothea Rutishauser; Natalia V Rivera; Charlotta Sandin; Sohel Mia; Vivianne Malmström; Åsa M Wheelock; Jan Wahlström; Rikard Holmdahl; Anders Eklund; Roman A Zubarev; Johan Grunewald; A Jimmy Ytterberg
Journal:  Mol Cell Proteomics       Date:  2016-07-24       Impact factor: 5.911

8.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

9.  Exploring the MHC-peptide matrix of central tolerance in the human thymus.

Authors:  Eleni Adamopoulou; Stefan Tenzer; Nina Hillen; Paula Klug; Ioanna A Rota; Silvia Tietz; Madlen Gebhardt; Stefan Stevanovic; Hansjörg Schild; Eva Tolosa; Arthur Melms; Christina Stoeckle
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 10.  How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors:  Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal:  Front Immunol       Date:  2014-04-15       Impact factor: 7.561

View more
  8 in total

Review 1.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

2.  The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.

Authors:  Juan Antonio Vizcaíno; Peter Kubiniok; Kevin A Kovalchik; Qing Ma; Jérôme D Duquette; Ian Mongrain; Eric W Deutsch; Bjoern Peters; Alessandro Sette; Isabelle Sirois; Etienne Caron
Journal:  Mol Cell Proteomics       Date:  2019-11-19       Impact factor: 5.911

3.  IgG Epitopes Processed and Presented by IgG+ B Cells Induce Suppression by Human Thymic-Derived Regulatory T Cells.

Authors:  Li-En Hsieh; John Sidney; Jane C Burns; David L Boyle; Gary S Firestein; Yoav Altman; Alessandro Sette; Alessandra Franco
Journal:  J Immunol       Date:  2021-02-12       Impact factor: 5.422

4.  Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.

Authors:  Li-En Hsieh; Jaeyoon Song; Adriana H Tremoulet; Jane C Burns; Alessandra Franco
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

Review 5.  Predicting Antigen Presentation-What Could We Learn From a Million Peptides?

Authors:  David Gfeller; Michal Bassani-Sternberg
Journal:  Front Immunol       Date:  2018-07-25       Impact factor: 7.561

Review 6.  Applying MAPPs Assays to Assess Drug Immunogenicity.

Authors:  Anette C Karle
Journal:  Front Immunol       Date:  2020-04-21       Impact factor: 7.561

Review 7.  The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design.

Authors:  Amy L Kessler; Marco J Bruno; Sonja I Buschow
Journal:  Vaccines (Basel)       Date:  2020-12-18

8.  Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.

Authors:  HuiSong Pak; Justine Michaux; Florian Huber; Chloe Chong; Brian J Stevenson; Markus Müller; George Coukos; Michal Bassani-Sternberg
Journal:  Mol Cell Proteomics       Date:  2021-04-09       Impact factor: 5.911

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.